BMJ Public Health (Mar 2024)

Cost-effectiveness of screening for developmental dysplasia of the hip in Karachi, Pakistan using a universally applicable cost-effectiveness model

  • Mansoor Ali Khan,
  • Muhammad Amin Chinoy,
  • Daniel Scott Corlew,
  • Hesham Gaafar,
  • Manon Pigeolet,
  • Dana Naamani,
  • Blake Christian Alkire,
  • Eduardo N Novais

DOI
https://doi.org/10.1136/bmjph-2023-000340
Journal volume & issue
Vol. 2, no. 1

Abstract

Read online

Introduction Developmental dysplasia of the hip (DDH) is a congenital anomaly of the hip socket that can lead to lifelong disability and pain when left untreated. DDH is a good candidate for screening because of its high frequency in population, availability of treatment and the possibility of secondary prevention. Pakistan currently does not have any systematic or universal neonatal screening programme for DDH.Methods The cost-effectiveness model in this study uses one decision tree for each screening scenario: (1) the status quo, (2) universal screening by clinical examination, (3) universal screening by clinical examination with targeted ultrasound (US) screening, (4) and universal screening by US. Loss of disability-adjusted life-years (DALYs) is used as outcome variable.Results When left untreated DDH creates a loss of 3.4 DALYs per person. Clinical examination and targeted US averts most DALYs per dollar spent. Generalised US averts more DALYs overall but requires a greater financial investment per DALY averted.Conclusions Universal US screening reaches more children and can be considered the more equitable approach but requires 10 times the financial investment clinical examination and targeted US requires. The decision which option is most appropriate for Karachi, Pakistan depends on resource availability, geography, infrastructure, treatment capacity, health system values and societal factors in Pakistan.